Interleukin 1 receptor blockade reduces tumor necrosis factor production, tissue injury, and mortality after hepatic ischemia-reperfusion in the rat

Transplantation

Volumn 63, Issue 1, 1997, Pages 143-148

  Shito, Masaya ^a   Wakabayashi, Go ^a   Ueda, Masakazu ^a   Shimazu, Motohide ^a   Shirasugi, Nozomu ^a   Endo, Masao ^a   Mukai, Makio ^a   Kitajima, Masaki ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; LIVER ISCHEMIA; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; SURVIVAL RATE; TISSUE INJURY;

ANIMALS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; ISCHEMIA; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; REPERFUSION INJURY; SIALOGLYCOPROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031032046     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199701150-00026     Document Type: Article

References (38)

1. Van Thiel DH, Schade RR, Hakala TR, Starzl TE, Denny D. Liver procurement for orthotopic transplantation: an analysis of the Pittsburgh experience. Hepatology 1984; 4 (suppl): 66.
2. Todo S, Nery J, Yanaga K, Podesta L, Gordon RD, Starzl TE. Extended preservation of human liver grafts with UW solution. JAMA 1989; 261: 711.
3. Johannigman JA, Johnson DJ, Roettger R. The effect of hypothermia on liver adenosine triphosphate (ATP) recovery following combined shock and ischemia. J Trauma 1992; 32: 190.
4. von Allmen D, Li S, Hasselgren PO, Fischer JE. Effect of ischemia on protein synthesis in the septic liver. Surg Gynecol Obstet 1991; 172: 441.
5. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470.
6. Tracey KJ, Lowry SF, Fahey TJ III, et al. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet 1987; 164: 415.
7. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA. Interleukin-1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988; 81: 1162.
8. Wakabayashi G, Gelfand JA, Jung WK, Connolly RJ, Burke JF, Dinarello CA. Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. J Clin Invest 1991; 87: 1925.
9. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin-8, a novel cytokine that activates neutrophils. J Clin Invest 1989; 84: 1045.
10. Sample AK, Czuprynski CJ. Priming and stimulation of bovine neutrophils by recombinant human interleukin-1 alpha and tumor necrosis factor alpha. J Leukoc Biol 1991; 49: 107.
11. Toledo-Pereyra LH, Suzuki S. Neutrophils, cytokines, and adhesion molecules in hepatic ischemia and reperfusion injury. J Am Coll Surg 1994; 179: 758.
12. Colletti LM, Burtch GD, Remick DG, et al. Production of tumor necrosis factor alpha and the development of pulmonary capillary injury following hepatic ischemia/reperfusion. Transplantation 1989; 49: 268.
13. Colletti LM, Remick DG, Burtch GD, Kunkel SL, Strieter RM, Campbell DA. Role of tumor necrosis factor-α in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. J Clin Invest 1990; 85: 1936.
14. Seckinger P, Williamson K, Balavoine JF, et al. A urine inhibitor of interleukin 1 activity affects both interleukin 1α and 1β but not tumor necrosis factor. J Immunol 1987; 139: 1541.
15. Arend WP, Joslin FG, Massoni RJ. Effects of immune complexes on production by human monocytes of interleukin-1 or interleukin-1 inhibitor. J Immunol 1985; 134: 3868.
16. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC. IL-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348: 550.
17. Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA. A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J 1991; 5: 338.
18. Hayashi H, Chaudry IH, Clemens MG, Baue AE. Hepatic ischemia models for determining the effects of ATP-MgC12 treatment. J Surg Res 1986; 40: 167.
19. Higgins GM, Anderson RM. Experimental pathology of the liver. Arch Pathol 1931; 12: 186.
20. Kawano K, Kim YI, Kaketani K, Kobayashi M. The beneficial effect of cyclosporine on liver ischemia in rats. Transplantation 1989; 48: 759.
21. Eisenberg SP, Evans RJ, Arend WP, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990; 343: 341.
22. Hannum CH, Wilcox CJ, Arend WP, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990; 343: 336.
23. Clark BD, Bedrosian I, Schindler R, et al. Detection of interleukin 1α and 1β in rabbit tissues during endotoxemia using sensitive radioimmunoassays. J Appl Physiol 1991; 71: 2412.
24. Nishida T, Nishino N, Takano M, et al. Molecular cloning and expression of rat interleukin-1α cDNA. J Biochem 1989; 105: 351.
25. Ikejima T, Okusawa S, van der Meer JWM, Dinarello CA. Induction by toxic-shock-syndrome toxin-1 of a circulating tumor necrosis factor-like substance in rabbits and of immunoreative tumor necrosis factor and interleukin-1 from human mononuclear cells. J Infect Dis 1988; 158: 1017.
26. Suzuki S, Toledo-Pereyra LH, Rodriguez FJ, Cejalvo D. Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. Modulating effects of FK506 and cyclosporine. Transplantation 1993; 55: 1265.
27. Shreeniwas R, Koga S, Karakurum M, et al. Hypoxia-mediated induction of endothelial cell interleukin-1α. An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Invest 1992; 90: 2333.
28. Koga S, Ogawa S, Kuwabara K, et al. Synthesis and release of interleukin 1 by reoxygenated human mononuclear phagocytes. J Clin Invest 1992; 90: 1007.
29. Suzuki S, Toledo-Pereyra LH. Interleukin 1 and tumor necrosis factor production as the initial stimulants of liver ischemia and reperfusion injury. J Surg Res 1994; 57: 253.
30. Dinarello CA, Cannon JG, Wolff SM, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces interleukin 1. J Exp Med 1986; 163: 1433.
31. Granowitz EV, Vannier E, Poutsiaka DD, Dinarello CA. Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: II. IL-1 receptor antagonist inhibits lipopolysaccharide-induced cytokine synthesis by human monocytes. Blood 1992; 79: 2364.
32. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627.
33. Corbett JA, Wang JL, Steetland MA, Lancaster JR Jr, McDaniel ML. Interleukin 1β induces the formation of nitric oxide by β-cells purified from rodent islets of Langerhans. J Clin Invest 1992; 90: 2384.
34. Sekido N, Mukaida N, Harada A, Nakanishi I, Watanabe Y, Matsushima K. Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature 1993; 365: 654.
35. Suzuki S, Toledo-Pereyra LH, Rodriguez FJ. Role of neutrophils during the first 24 hours after liver ischemia and reperfusion injury. Transplant Proc 1994; 26: 3695.
36. Arend WP, Welgus HG, Thompson RC, Eisenberg SP. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest 1990; 85: 1694.
37. Cominelli F, Nast CC, Clark BD, et al. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 1990; 86: 972.
38. Fischer E, Marano MA, Van Zee KJ, et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992; 89: 1551.